In the BioHarmony Drug Report Database

"Preview" Icon

Alemtuzumab

Campath, Lemtrada (alemtuzumab) is an antibody pharmaceutical. Alemtuzumab was first approved as Campath on 2001-05-07. It is used to treat b-cell chronic lymphocytic leukemia in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against CAMPATH-1 antigen.

 

Trade Name

 

Lemtrada
 

Common Name

 

alemtuzumab
 

ChEMBL ID

 

CHEMBL1201587
 

Indication

 

b-cell chronic lymphocytic leukemia, multiple sclerosis
 

Drug Class

 

Monoclonal antibodies: humanized, tumors as target

Image (chem structure or protein)

Alemtuzumab structure rendering